Spots Global Cancer Trial Database for A Study to Assess Safety and Tolerability of CC-486 (ONUREG®, Oral Azacitidine) in Combination Therapy in Participants With Acute Myeloid Leukemia (AML)
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: A Study to Assess Safety and Tolerability of CC-486 (ONUREG®, Oral Azacitidine) in Combination Therapy in Participants With Acute Myeloid Leukemia (AML)
Official Title: A Phase 1B, Open-label, Global, Multicenter, Dose Determination Study to Evaluate Safety, Tolerability, and Preliminary Efficacy of CC-486 (ONUREG®) in Combination Therapy in Subjects With Acute Myeloid Leukemia (AML)
Study ID: NCT04887857
Conditions
Study Description
Brief Summary: The purpose of this study is to evaluate the safety, tolerability, and preliminary efficacy of CC-486 (ONUREG®) in combination with venetoclax in relapsed and/or refractory Acute Myeloid Leukemia (AML) and newly diagnosed AML.
Detailed Description:
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Local Institution - 104, Stanford, California, United States
Local Institution - 110, Denver, Colorado, United States
Local Institution - 105, Boston, Massachusetts, United States
Local Institution - 106, New York, New York, United States
Local Institution - 113, New York, New York, United States
Local Institution - 102, Cleveland, Ohio, United States
Local Institution - 111, Oklahoma City, Oklahoma, United States
Local Institution - 101, Houston, Texas, United States
Local Institution - 202, North Melbourne, Victoria, Australia
Local Institution - 201, Melbourne, , Australia
Contact Details
Name: Bristol-Myers Squibb
Affiliation: Bristol-Myers Squibb
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
